Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation
We present the first report of use of recombinant human parathyr oid hormone (1-84) (rhPTH(1-84)) in a hypoparathyroid patient during early pregnancy and lactation. The patient developed postoperative hypoparathyroidism as a 28-year-old woman following total thyroidectomy for multinodular goiter. Sh...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-06-01
|
| Series: | Endocrinology, Diabetes & Metabolism Case Reports |
| Online Access: | https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM22-0401.xml |
| _version_ | 1797795213915193344 |
|---|---|
| author | E Pauline Liao Natalie E Cusano |
| author_facet | E Pauline Liao Natalie E Cusano |
| author_sort | E Pauline Liao |
| collection | DOAJ |
| description | We present the first report of use of recombinant human parathyr oid hormone (1-84) (rhPTH(1-84)) in a hypoparathyroid patient during early pregnancy and lactation. The patient developed postoperative hypoparathyroidism as a 28-year-old woman following total thyroidectomy for multinodular goiter. She was not well controlled with conventional therapy, and started rhPTH(1-84) in 2015 following its approval in the United States. She became pregnant in 2018 at age 40. She discontinued rhPTH(1-84) therapy at 5 weeks gestation but resumed in the postpartum period while breastfeeding. Her daughter’s serum calcium was borderline elevated at 8 days postpartum but within the normal range at 8 weeks postpartum. The patient stopped nursing at around 6 months postpartum. Her daughter is now at 4 years and 5 months of age and is healthy and meeting developmental milestones. She was again pregnant at 8 months postpartum from her first pregnancy, and she made an informed decision to continue parathyroid hormone. At 15 weeks gestation, rhPTH(1-84) was recalled in the United States due to issues with the delivery device, and she discontinued rhPTH(1-84) treatment and resumed calcium and calcitriol supplements. She gave birth to a baby boy at 39 weeks in January 2020. At 3 years and 2 months of age, he is overall healthy. Further data are needed regarding the safety of rhPTH(1-84) in pregnancy and lactation. |
| first_indexed | 2024-03-13T03:14:31Z |
| format | Article |
| id | doaj.art-ef63433b543c4e26a634d330a069cafd |
| institution | Directory Open Access Journal |
| issn | 2052-0573 |
| language | English |
| last_indexed | 2024-03-13T03:14:31Z |
| publishDate | 2023-06-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrinology, Diabetes & Metabolism Case Reports |
| spelling | doaj.art-ef63433b543c4e26a634d330a069cafd2023-06-26T05:57:43ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732023-06-01111510.1530/EDM-22-0401Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactationE Pauline Liao0Natalie E Cusano1Department of Medicine, Division of Endocrinology, Lenox Hill Hospital, New York, New York, USADepartment of Medicine, Division of Endocrinology, Lenox Hill Hospital, New York, New York, USAWe present the first report of use of recombinant human parathyr oid hormone (1-84) (rhPTH(1-84)) in a hypoparathyroid patient during early pregnancy and lactation. The patient developed postoperative hypoparathyroidism as a 28-year-old woman following total thyroidectomy for multinodular goiter. She was not well controlled with conventional therapy, and started rhPTH(1-84) in 2015 following its approval in the United States. She became pregnant in 2018 at age 40. She discontinued rhPTH(1-84) therapy at 5 weeks gestation but resumed in the postpartum period while breastfeeding. Her daughter’s serum calcium was borderline elevated at 8 days postpartum but within the normal range at 8 weeks postpartum. The patient stopped nursing at around 6 months postpartum. Her daughter is now at 4 years and 5 months of age and is healthy and meeting developmental milestones. She was again pregnant at 8 months postpartum from her first pregnancy, and she made an informed decision to continue parathyroid hormone. At 15 weeks gestation, rhPTH(1-84) was recalled in the United States due to issues with the delivery device, and she discontinued rhPTH(1-84) treatment and resumed calcium and calcitriol supplements. She gave birth to a baby boy at 39 weeks in January 2020. At 3 years and 2 months of age, he is overall healthy. Further data are needed regarding the safety of rhPTH(1-84) in pregnancy and lactation.https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM22-0401.xml |
| spellingShingle | E Pauline Liao Natalie E Cusano Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation Endocrinology, Diabetes & Metabolism Case Reports |
| title | Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation |
| title_full | Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation |
| title_fullStr | Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation |
| title_full_unstemmed | Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation |
| title_short | Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation |
| title_sort | use of rhpth 1 84 for hypoparathyroidism during early pregnancy and lactation |
| url | https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM22-0401.xml |
| work_keys_str_mv | AT epaulineliao useofrhpth184forhypoparathyroidismduringearlypregnancyandlactation AT natalieecusano useofrhpth184forhypoparathyroidismduringearlypregnancyandlactation |